JPM 2024: Intuitive And J&J Both Weigh In On Growth For 2024

The two medtech giants – both of which will soon be releasing new robotic systems – spoke about growth targets and opportunities going into 2024.

J.P. Morgan 2024 — • Source: Shutterstock

Johnson & Johnson immediately made it presence felt at this year’s J.P. Morgan Healthcare Conference in San Francisco by announcing its latest $2bn bet on the antibody-drug conjugates through its acquisition of Ambrx Biopharma.

Central to this acquisition are Ambrx’s lead assets – drugs targeting castration-resistant prostate cancer, metastatic HER2+ breast cancer and renal...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Roche Diagnostics Day 2025: ‘We Need To Become A Leader In Decentralized Testing’

29 May 2025

• By Natasha Barrow

Roche aims to grow its diagnostics sales by mid to high single digits, said CEO of Roche Diagnostics Matt Sause. The company unveiled the Axelios synthesis and sequencing solution and discussed its “long-term commitment” to China, as well as its business strategy for the next five years.

Industry Execs Talk Tariff Turbulence During MD&M East

27 May 2025

• By Brian Bossetta

During MD&M East in Manhattan last week, a panel of experts discussed how the Trump administration’s trade policy is affecting manufacturing and offered some ideas on what manufacturers can do to help mitigate the chaos.

German Bionic Launches ‘Strongest Exoskeleton To Date’